James Mulay sold $852k of CGON
director at CG Oncology, Inc.. 27,015 shares at an average of $31.53, traded Sep 5, 2025, filed Sep 8, 2025.
Score components
- +15RoleDirector
- +23Trade size$852k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113556, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 5, 2025 | MOption exercise Common Stock10b5-1 | +27,015 | $0.60 | $16k | 27,015 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -12,342 | $30.47 | $376k | 14,673 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -4,095 | $31.42 | $129k | 10,578 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -7,465 | $32.64 | $244k | 3,113 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -3,113 | $33.22 | $103k | 0 | Sep 8, 2025 |
| Sep 5, 2025 | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -27,015 | $0.00 | $0 | 0 | Sep 8, 2025 |
Related signals
Other insiders at CG Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $73k 1,000 shares | -100% | |
| 10Weak | CG Oncology, Inc. | James Mulay director | $125k 1,964 shares | -300% | |
| 19Weak | CG Oncology, Inc. | James Mulay director | $585k 11,145 shares | -1704% | |
| 6Weak | CG Oncology, Inc. | Leonard E Post director | $41k 1,000 shares | -100% | |
| 14Weak | CG Oncology, Inc. | Leonard E Post director | $43k 1,000 shares | -100% | |
| 21Weak | CG Oncology, Inc. | James Mulay director | $260k 5,903 shares | -100% | |
| 20Weak | CG Oncology, Inc. | Leonard E Post director | $200k 5,000 shares | -100% | |
| 26Weak | CG Oncology, Inc. | James Mulay director | $500k 12,755 shares | -100% | |
| 31Weak | CG Oncology, Inc. | James Mulay director | $885k 22,686 shares | -119% | |
| 21Weak | CG Oncology, Inc. | Leonard E Post director | $35k 1,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.